Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Aquestive Therapeutics, Inc. (AQST)
|
Add to portfolio |
|
|
|
| Price: |
$4.09
| | Metrics |
| OS: |
61.7
|
B
| |
|
|
| Market cap: |
$252
|
B
| |
|
|
|
Net debt:
|
$16.7
|
M
| |
|
|
|
EV:
|
$252
|
B
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
|
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 |
| Revenues | 47.7 | 50.8 | 45.8 | 52.6 | 67.4 | 66.9 | 67.1 |
| Revenue growth | -6.2% | 10.9% | -12.8% | -22.0% | 0.8% | -0.3% | |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 20.4 | 0.0 | 0.0 | 31.8 |
| Gross profit | 47.7 | 50.8 | 45.8 | 32.2 | 67.4 | 66.9 | 35.3 |
| Gross margin | 100.0% | 100.0% | 100.0% | 61.3% | 100.0% | 100.0% | 52.6% |
| Selling, general and administrative | 52.9 | 53.5 | 55.9 | 64.3 | 72.3 | 25.1 | 20.8 |
| Research and development | 17.5 | 17.0 | 19.9 | 20.6 | 23.1 | 22.1 | |
| EBITA | -42.0 | -34.6 | -42.8 | -52.6 | -48.9 | -0.1 | -0.8 |
| EBITA margin | -88.0% | -68.1% | -93.4% | -100.0% | -72.5% | -0.1% | -1.2% |
| Amortization of intangibles | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 |
| EBIT | -42.1 | -34.7 | -42.9 | -52.7 | -48.9 | -0.1 | -0.8 |
| EBIT margin | -88.2% | -68.2% | -93.6% | -100.1% | -72.6% | -0.2% | -1.3% |
| Pre-tax income | -54.4 | -70.5 | -55.8 | -66.2 | -61.4 | -8.9 | -9.6 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -54.4 | -70.5 | -55.8 | -66.2 | -61.4 | -11.4 | -9.6 |
| Net margin | -114.1% | -138.8% | -121.7% | -125.9% | -91.0% | -17.1% | -14.3% |
| |
| Diluted EPS | ($1.12) | ($1.85) | ($1.66) | ($2.61) | ($2.96) | | |
| Shares outstanding (diluted) | 48.7 | 38.1 | 33.7 | 25.4 | 20.7 | | |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|